Rhythm Pharmaceuticals Announced That The National Institute For Health And Care Excellence Issued Guidance That Recommends Imcivree (setmelanotide) As An Option For Treatment Of Obesity And Hyperphagia In Patients With Bardet-biedl Syndrome
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals announced that the National Institute for Health and Care Excellence (NICE) has issued guidance recommending Imcivree (setmelanotide) for the treatment of obesity and hyperphagia in patients with Bardet-Biedl Syndrome.
May 22, 2024 | 8:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals received a positive recommendation from NICE for its drug Imcivree (setmelanotide) to treat obesity and hyperphagia in Bardet-Biedl Syndrome patients. This regulatory approval could boost the company's market position and drive short-term stock price gains.
The NICE recommendation is a significant regulatory milestone for Rhythm Pharmaceuticals, potentially increasing the adoption of Imcivree and driving revenue growth. This positive development is likely to have a favorable impact on RYTM's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100